Vsee Health regains Nasdaq compliance after equity increase
DUBLIN - Investment firm Janus Henderson Group plc has disclosed a 6.01% ownership position in Avadel Pharmaceuticals plc, according to a regulatory filing published today.
The disclosure, made under Irish Takeover Panel rules, reveals that Janus Henderson holds 5,940,860 ordinary shares in the pharmaceutical company as of October 23, 2025. The filing notes that Janus Henderson lacks discretion regarding voting decisions for 104,357 of these shares.
The document also details recent transactions, including the sale of 95,472 Avadel shares at a price of $18.50 per share and an additional 19 shares at $18.52 per share. A separate transaction involved an in-specie transfer of 2,620 shares.
Irish takeover regulations require disclosure when an entity's stake in a company reaches or exceeds 1% during an offer period. Such filings provide transparency about significant shareholders and their recent trading activity.
The filing indicates that Janus Henderson does not have any indemnity arrangements, options, or other agreements relating to Avadel securities.
Avadel Pharmaceuticals, headquartered in Ireland, develops pharmaceutical products focused on central nervous system disorders.
This information was disclosed through a Form 8.3 filing with the Irish Takeover Panel, which requires public disclosure of significant holdings in companies potentially involved in takeover situations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.